Fennec Pharmaceuticals Announces Third Quarter 2023 Financia

~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October...

Related Keywords

Oregon , United States , Rosty Raykov , Robert Andrade , Lindsay Rocco , Landierw Ototoxicity , Oregon Health , Company In Europe , European Commission Marketing Authorization , Drug Administration , Children Oncology Group , Science University , Healthcare Products Regulatory Agency , Clinical Oncology Group , Exchange Commission , Nasdaq , Elixir Health Public Relations , Fennec Pharmaceuticals Inc , Fennec Pharmaceuticals , Development Rd Expenses , Net Product Revenue , Increase Compared , Second Quarter , Received Approval , Host Conference Call Today , Marketing Expenses , Event Calendar , Liability Data , Prescribing Information , Orphan Drug Exclusivity , Pediatric Use Marketing Authorization , Annual Report , Cisplatin Ototoxicity , Current Opinion , Hearing Loss , Adolescent Cancers , Pediatric Blood , Markets ,